Lack of very strong association between pre-treatment fibrinogen and PAI-1 with long-term mortality after coronary bypass surgery
(2007) In Cardiology 108(2). p.82-89- Abstract
- Aim: To explore the association between the coagulation protein fibrinogen and the fibrinolytic biomarker plasminogen activator inhibitor-1 ( PAI- 1) and the long- term mortality after coronary artery bypass grafting ( CABG). Patients and Methods: In 729 patients undergoing CABG at Sahlgrenska University Hospital, a blood sample for fibrinogen and PAI-1 was collected prior to the procedure. Patients were followed for 10 years. Results: Among patients with high levels of fibrinogen (> 3.6 g/ l; median), the 10-year mortality was 32.3 vs. 20.7% among patients with fibrinogen levels below the median ( p = 0.0005). However, patients with higher levels of fibrinogen were older and had an adverse risk factor pattern. When adjusting for these... (More)
- Aim: To explore the association between the coagulation protein fibrinogen and the fibrinolytic biomarker plasminogen activator inhibitor-1 ( PAI- 1) and the long- term mortality after coronary artery bypass grafting ( CABG). Patients and Methods: In 729 patients undergoing CABG at Sahlgrenska University Hospital, a blood sample for fibrinogen and PAI-1 was collected prior to the procedure. Patients were followed for 10 years. Results: Among patients with high levels of fibrinogen (> 3.6 g/ l; median), the 10-year mortality was 32.3 vs. 20.7% among patients with fibrinogen levels below the median ( p = 0.0005). However, patients with higher levels of fibrinogen were older and had an adverse risk factor pattern. When adjusting for these differences, pre- operative fibrinogen levels did not clearly appear as an independent predictor of long- term mortality. The 10- year mortality was similar in patients with high ( 25.3%) and low ( 26.5%) levels of PAI-1. Conclusion: Our results do not suggest that fibrinogen and PAI- 1, when evaluated prior to the operative procedure, arestrongly associated with increased mortality in the longterm after CABG, when other co-morbidity factors are simultaneously considered. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/648152
- author
- Sjoland, Helen ; Tengborn, Lilian LU ; Stensdotter, Lillemor and Herlitz, Johan
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- prognosis, fibrinogen, coronary artery surgery, plasminogen activator, inhibitor
- in
- Cardiology
- volume
- 108
- issue
- 2
- pages
- 82 - 89
- publisher
- Karger
- external identifiers
-
- wos:000247435400003
- scopus:34548096986
- ISSN
- 1421-9751
- DOI
- 10.1159/000095935
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)
- id
- e37b5d81-8a2c-4030-aea1-484e36a86606 (old id 648152)
- date added to LUP
- 2016-04-01 12:00:23
- date last changed
- 2022-01-26 21:28:25
@article{e37b5d81-8a2c-4030-aea1-484e36a86606,
abstract = {{Aim: To explore the association between the coagulation protein fibrinogen and the fibrinolytic biomarker plasminogen activator inhibitor-1 ( PAI- 1) and the long- term mortality after coronary artery bypass grafting ( CABG). Patients and Methods: In 729 patients undergoing CABG at Sahlgrenska University Hospital, a blood sample for fibrinogen and PAI-1 was collected prior to the procedure. Patients were followed for 10 years. Results: Among patients with high levels of fibrinogen (> 3.6 g/ l; median), the 10-year mortality was 32.3 vs. 20.7% among patients with fibrinogen levels below the median ( p = 0.0005). However, patients with higher levels of fibrinogen were older and had an adverse risk factor pattern. When adjusting for these differences, pre- operative fibrinogen levels did not clearly appear as an independent predictor of long- term mortality. The 10- year mortality was similar in patients with high ( 25.3%) and low ( 26.5%) levels of PAI-1. Conclusion: Our results do not suggest that fibrinogen and PAI- 1, when evaluated prior to the operative procedure, arestrongly associated with increased mortality in the longterm after CABG, when other co-morbidity factors are simultaneously considered.}},
author = {{Sjoland, Helen and Tengborn, Lilian and Stensdotter, Lillemor and Herlitz, Johan}},
issn = {{1421-9751}},
keywords = {{prognosis; fibrinogen; coronary artery surgery; plasminogen activator; inhibitor}},
language = {{eng}},
number = {{2}},
pages = {{82--89}},
publisher = {{Karger}},
series = {{Cardiology}},
title = {{Lack of very strong association between pre-treatment fibrinogen and PAI-1 with long-term mortality after coronary bypass surgery}},
url = {{http://dx.doi.org/10.1159/000095935}},
doi = {{10.1159/000095935}},
volume = {{108}},
year = {{2007}},
}